MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

2 years ago

LA JOLLA, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and…

New research finds Imprivata digital identity solutions accelerated emergency COVID-19 vaccine delivery for Northern Ireland Public Health Service

2 years ago

The company’s single sign-on and identity governance solutions helped Health and Social Care (HSC) Trust onboard 500 personnel in under…

Mainz Biomed Secures up to $50M in New Funding

2 years ago

Provides option to access capital to support commercial and clinical programsBERKELEY, Calif. and MAINZ, Germany, June 29, 2023 (GLOBE NEWSWIRE)…

BioPorto Announces Submission of Response to FDA Additional Information Letter

2 years ago

June 29, 2023News release BioPorto Announces Submission of Response to FDA Additional Information Letter COPENHAGEN, DENMARK and BOSTON, MA, June…

EssilorLuxottica and Jimmy Choo announce a ten-year licensing agreement

2 years ago

EssilorLuxottica and Jimmy Chooannounce a ten-year licensing agreement Charenton-le-Pont, France and London, UK (June 29, 2023 – 8:00 am CEST) –…

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

2 years ago

SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…

Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease

2 years ago

  Vaccines Investor EventVaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease Sanofi reaffirms ambition to…

Santhera Publishes Timeline of the Reverse Share Split

2 years ago

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL…

CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

2 years ago

BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…